checkAd

    DGAP-News  142  0 Kommentare Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price

    DGAP-News: ABIVAX / Key word(s): Miscellaneous
    Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price

    02.11.2020 / 14:00
    The issuer is solely responsible for the content of this announcement.


    Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price

    PARIS, November 02, 2020 - 2:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces that its senior management will host a webcast and teleconference on Tuesday, November 3, 2020 at 3:00 pm CET (Paris time), to discuss the recently announced oversubscribed capital increase of EUR 28m at market price, company developments as well as address questions.

    Attendees can participate by weblink (https://channel.royalcast.com/webcast/abivaxwebcast/20201103_1/) or connect by phone using the following telephone numbers.


    Dial in details for participants:

    France: +33 (0) 1 7037 7166

    UK (Standard International Access): +44 (0) 20 3003 2666

    U.S.: +1 212 999 6659

    Belgium: +32 (0) 2 789 8603

    Password: abivax


    About Abivax (www.abivax.com)

    Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
    More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.



    Contacts


    Abivax
    Communications
    Regina Jehle
    regina.jehle@abivax.com
    +33 6 24 50 69 63

    Investors
    LifeSci Advisors
    Chris Maggos
    chris@lifesciadvisors.com
    +41 79 367 6254

    Press Relations & Investors Europe
    MC Services AG
    Anne Hennecke
    anne.hennecke@mc-services.eu
    +49 211 529 252 22

    Public Relations France
    Actifin
    Ghislaine Gasparetto
    ggasparetto@actifin.fr
    +33 6 21 10 49 24

    Public Relations France
    DGM Conseil
    Thomas Roborel de Climens
    thomasdeclimens@dgm-conseil.fr
    +33 6 14 50 15 84

    Public Relations USA
    Rooney Partners LLC
    Marion Janic
    mjanic@rooneyco.com
    +1 212 223 4017


    02.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de


    1144669  02.11.2020 

    fncls.ssp?fn=show_t_gif&application_id=1144669&application_name=news&site_id=wallstreet

    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price 02.11.2020 / 14:00 The issuer is solely responsible for the content of this …